Short Interest in Midatech Pharma plc (NASDAQ:MTP) Decreases By 28.8%

Midatech Pharma plc (NASDAQ:MTPGet Rating) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 30,100 shares, a drop of 28.8% from the March 31st total of 42,300 shares. Based on an average trading volume of 57,300 shares, the days-to-cover ratio is currently 0.5 days.

NASDAQ:MTP traded down $0.03 during trading hours on Monday, hitting $0.65. 239 shares of the company were exchanged, compared to its average volume of 62,526. Midatech Pharma has a one year low of $0.65 and a one year high of $3.61. The company has a fifty day simple moving average of $0.89 and a 200 day simple moving average of $1.17.

A number of large investors have recently made changes to their positions in MTP. Citadel Advisors LLC bought a new position in Midatech Pharma during the 4th quarter worth $44,000. Morgan Stanley raised its position in Midatech Pharma by 392.4% during the 1st quarter. Morgan Stanley now owns 92,505 shares of the company’s stock worth $197,000 after purchasing an additional 73,719 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Midatech Pharma by 4.1% during the 3rd quarter. Renaissance Technologies LLC now owns 219,137 shares of the company’s stock worth $381,000 after purchasing an additional 8,652 shares during the last quarter. 5.53% of the stock is owned by institutional investors and hedge funds.

Midatech Pharma Company Profile (Get Rating)

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection.

Further Reading

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with's FREE daily email newsletter.